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INTRODUCTION
 Statins are a group of cholesterol lowering drugs 
which inhibit HMG-CoA reductase, a key enzyme 
in the cholesterol biosynthesis. They have a well-
established role in decreasing serum concentration 
of low density lipoprotein (LDL) cholesterol, thereby 
reducing the risk of atherosclerotic cardiovascular 
disease (CVD).1 A Cochrane review in 2013 has 
indicated a role of statins in the primary prevention 
of CVD in people with no history of this disease.2 
An association between CVD risk and vitamin D 
deficiency has also been reported in a number of 
studies.3,4
 The deficiency of vitamin D is a global health 
problem and its prevalence is very high in South 
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Lack of association of statin use with Vitamin D
levels in a hospital based population of 
type 2 diabetes mellitus patients
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ABSTRACT
Objective: To investigate the relationship of statins (drug given to reduce serum levels of LDL-cholesterol) 
on vitamin D levels of Pakistani type 2 diabetes mellitus (DM) patients in a hospital in Karachi.
Methods: In a cross-sectional survey, 312 consecutive patients with type 2 DM (219 males and 93 females, 
age 22-70 years) were recruited with informed consent. A questionnaire was administered to find out 
whether they were statin users or non-users. Serum was analyzed for concentrations of 25(OH) vitamin D 
[25(OH)D] and other related biomarkers such as serum cholesterol, triglycerides, HDL-cholesterol, LDL-
cholesterol, phosphate and calcium using kit methods. Multiple Linear Regression was used to evaluate 
association of statin use with serum levels of vitamin D while adjusting for related covariates including 
duration of statin use, duration of type 2 DM and smoking.
Results: Mean concentrations of serum cholesterol, and LDL-cholesterol were lower among statin users 
compared to statin non-users (P < 0.01), while HDL-cholesterol levels were higher (P<0.01). No relationship 
was observed between statin use and serum levels of vitamin D (P=0.768), when adjusted for age, gender, 
BMI, duration of type 2 DM, smoking, serum cholesterol and LDL-cholesterol. The adjusted regression 
coefficient (β) and standard error [SE(β)] for statin use duration were 0.012 (0.042), when serum levels of 
vitamin D was taken as an outcome.
Conclusion: Lack of association was found between statin use and vitamin D levels in a hospital-based 
population of Pakistani patients with type 2 DM.
KEY WORDS: Diabetes mellitus, Pakistani population, Statins, Vitamin D levels.
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Asian populations including Pakistan.5,6 A few 
studies have shown that statins significantly 
increase serum levels of vitamin D metabolite, 
25-hydroxyvitamin D (25(OH)D).7,8 However, a 
recent systematic review and meta-analysis of 
7 studies including 5 randomized clinical trials 
showed no significant effect of statin treatment 
on plasma levels of vitamin D.9 It has even been 
suggested that statin therapy may impair vitamin D 
status, thereby leading to increased risk of CVD.10,11 
More recently, a meta-analysis on the effect of statins 
on vitamin D levels was inconclusive and reported 
“conflicting directions of effects from interventional 
and observation studies”.12
 Since no studies have been carried out on South 
Asian population on the relationship of statin use 
and vitamin D status, we embarked on investigating 
this relationship in Pakistani diabetic patients who 
are often put on statins to reduce CVD risk while 
managing the blood glucose levels. Therefore, the 
objective of this study was to find out if there is any 
association between statin use and vitamin D levels 
in a hospital based population of Pakistani patients 
with type 2 diabetes mellitus (DM).
METHODS
 In a cross-sectional survey for the assessment of 
the role of statins on vitamin D levels in type 2 DM 
patients, 312 consecutive patients (age 22-70 years; 
219 males and 93 females) were recruited from the 
Endocrinology Clinics of the Aga Khan University 
Hospital (AKUH) with informed consent. These 
patients had confirmed diagnosis of type 2 DM 
on the basis of clinical history and fasting serum 
glucose > 126 mg/dl as per guidelines of the 
International Diabetes Federation. According to the 
inclusion criteria, they had not been taking vitamin 
D supplements for the last 6 months and were not 
suffering from any of the chronic diseases such as 
tuberculosis, liver disease, uremia or cancer and 
were not pregnant. Majority of the recruited patients 
(65%) were newly diagnosed diabetes patients with 
duration of diabetes less than 6 months. Seventeen 
percent of patients had duration of the disease for 
more than 60 months. All the patients were on oral 
hypoglycemic drugs. Those on statins had been on 
daily dosages 5 mg (13%), 10 mg (55%) and 20 mg 
(32%). The study had been approved by the Ethics 
Review Committee of the Aga Khan University.
 A brief questionnaire was used for demographic 
information and to find out whether they were 
using statins or not. Ten ml fasting (at least 4 
hours) blood was collected and serum/plasma 
was analyzed for 25(OH) vitamin D [25(OH)D], 
cholesterol, LDL-cholesterol, HDL-cholesterol, 
triglycerides, phosphate and calcium using kit 
Table-I: Demographic and clinical characteristics of type 2 DM patients with respect to statin use and non-use.
Variable
Statin nonusers
(n=160) Mean±SD
Statin users
(n=152) Mean±SD P*
n(%) n(%)
Gender
  Males (n=219)
  Females (n=93)
108(67.5)
52(32.5)
-
-
111(73)
41(27)
-
-
0.29
Smoker (current)
  No
  Yes
128(80)
32(20)
-
-
122(80.3)
30(19.7)
-
-
0.95
Duration of DM (months) - 35.8±46.8 - 63.9±70.3 <0.01
Age (yr) - 45.6±10.5 - 50.8±8.7 <.01
BMI (kg/m2) - 29.8±5.5 - 29.9±5.2 0.22
Serum cholesterol (mg/dl) - 162±48 - 127±46 <0.01
Triglyceride (mg/dl) - 160±86 - 144±72 0.08
HDL-cholesterol (mg/dl) - 25.03±7.80 - 29.29±8.91 <0.01
LDL-cholesterol (mg/dl) - 90±36 - 63±39 <0.01
Phosphate (mg/dl) - 3.6±0.70 - 3.75±0.74 0.27
Calcium (mg/dl) - 9.93±1.8 - 9.71±1.93 0.30
25(OH)D (ng/ml) - 18.62±11.63 - 20.3±11.6 0.23
*P was obtained by comparing mean values of two groups (statin users and non-users) using Independent samples t 
test, while percentages in the two groups (statin users and non-users) were compared using chi square.
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methods (Roche Diagnostics Indianapolis, IN). 
For quality assurance, standard controls with high 
and low concentrations of biomarkers were run 
along with the test samples.
Statistical analysis: Statistical analyses were 
carried out using Statistical Package for Social 
Sciences® (SPSS) software version 19 for Windows® 
(Apache Software Foundation, USA). Mean values 
of continuous variables such as age, BMI, serum 
levels of cholesterol, triglyceride, HDL-cholesterol, 
LDL-cholesterol, phosphate, calcium, 25(OH)D, 
duration of diabetes and duration of statin use were 
expressed as mean±SD, while categorical variables 
such as gender and smoking status were expressed 
as n(%). Mean values of variables in two groups 
(statin users and statin non-users) were compared 
using Independent sample t test. Multiple linear 
regression was used to observe the relationship 
between vitamin D levels and statin use, which was 
also adjusted for demographic and health related 
covariates.
RESULTS
 As shown in Table I, mean age and duration 
of diabetes in the statin non-users group were 
significantly lower compared to the statin users 
group (P < 0.01). Similarly, mean concentrations 
of serum cholesterol and LDL cholesterol were 
significantly lower in the statin users group 
compared to the non-users group (P < 0. 01). 
However, HDL-cholesterol levels were significantly 
higher in the statin users group (P < 0.01). No 
significant difference was found when the mean 
values of 25(OH)D between statin-users and statin 
non-users were compared using Independent 
sample t test (P = 0.23). No significant differences 
with respect to other variables were found between 
the two groups.
 Regarding mean duration of statin use and 
dosages of statins, out of 152 statin users, the data 
of 118 were available for regression analysis. Mean 
duration of statin treatment among the statin users 
group was 17.99±21.42 months, while the mean 
dosage of statins in this group was 12.7±5.3 mg.
 The effect of different factors, particularly duration 
of statin use is shown in Table II. Gender, age, BMI, 
duration of DM, levels of serum cholesterol, HDL-
cholesterol and calcium were found to be significant 
at the univariate level.
Statin use and Vitamin D levels
Table-II: Effect of statin use on the serum levels of vitamin D using multiple linear regression.
Variable Crude
β[SE(β)]**
P Adjusted*
β[SE(β)]**
P
Statin use duration (months) 0.07(0.039) 0.076 0.012(0.042) 0.768
Age (yr) 0.227(0.067) 0.001 0.117(0.071) 0.099
Gender
  Male (Ref.)***
  Female
-
3.176(1.47)
-
0.031 3.496(1.47)
0.018
-
-
BMI (kg/m2) -0.338(0.133) 0.005 -0.294(0.132) 0.027
Type 2 DM duration (months) 0.041(0.011) <0.001 0.035(0.013) 0.006
Current Smoking
  No (Ref.)***
  Yes
-
-
-1.495(1.728)
0.388
-
-
-
-
0.974(1.765)
0.582
-
-
Cholesterol (mg/dl) -0.28(0.014) 0.043 -0.057(0.019) 0.003
LDL-C (mg/dl) -0.011(0.017) 0.500 0.062(0.024) 0.01
HDL-C (mg/dl) 0.16(0.076) 0.035 - -
Triglyceride (mg/dl) 0.006(0.008) 0.468 - -
Phosphate (mg/dl) -0.455(0.913) 0.618 - -
Calcium (mg/dl) -0.714(0.353) 0.044 - -
Constant - - 22.915(5.740) <0.001
*Model was adjusted for age, gender, BMI, duration of type 2 diabetes mellitus, current smoking, serum cholesterol 
and LDL-cholesterol with coefficient of determination (R2)= 0.135.
** β[SE(β)] refers to regression co-efficient with its standard error.
***Ref. indicates the reference group category in regression.
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 At multivariable level, when the relationship 
between duration of statin use and serum level of 
vitamin D was adjusted for other factors, which 
were either biologically important or significant 
at the univariate level, the variables like gender, 
BMI, duration of type 2 diabetes, serum levels of 
cholesterol and LDL-cholesterol were found to be 
significantly associated.
 Current smoking was kept in the model because 
of its biological importance.6 Regarding the duration 
of statin use, one month increase in statin use was 
found to be responsible for an average increase in 
vitamin D level by 0.012 ng/ml when adjusted for 
age, gender, BMI, duration of type 2 DM, current 
smoking, serum cholesterol and LDL-cholesterol. 
The value of coefficient of determinations (R2) 
of 0.135 indicates that 13.5% variation in serum 
level of vitamin D is explained by the investigated 
covariates.
DISCUSSION
 There are numerous reports about high preva-
lence of hypovitominosis D in South Asian general 
population as well as patients with type 2 DM.13-15 
Since diabetic patients have an additional risk of 
developing CVD, they are often prescribed statins 
to control their LDL cholesterol along with usual 
management of their serum glucose level. Howev-
er, long-term use of statins may produce hepatotox-
icity. Since cholesterol metabolism and vitamin D 
both share a common metabolic pathway, it is possi-
ble that prolonged use of statins would not only in-
hibit cholesterol biosynthesis but also reduce levels 
of 7-dehydrocholesterol, a precursor molecule for 
vitamin D3, thereby leading to low concentration of 
vitamin D in the body.16 This would render such pa-
tients vulnerable to risks associated with vitamin D 
deficiency. However, in the present study we found 
no difference in serum levels of vitamin D in statin 
users and non-users in type 2 DM patients. Similar 
findings have been reported by Ertugrul et al, who 
have shown no significant effect of pravastatin and 
fluvastatin on serum levels of 25(OH)D.17 In a rand-
omized controlled trial on healthy postmenopausal 
women, simvastatin was found to have no effect on 
vitamin D status even after 52 weeks of treatment.18 
Similar results have been found by Mazidi et al on 
an Iranian population of patients with dyslipidem-
ia.19 On the contrary, Sathyapalan et al have report-
ed increased concentration of 25(OH)D following 
therapy with atorvastatin in type 2 DM patients in 
UK.20 Similarly, 4 studies (two carried out in Tur-
key, one in Spain and another one in Germany) have 
also shown increased serum levels of 25(OH)D fol-
lowing treatment with rosuvastatin and atorvasta-
tin.8,17,21,22 Most of these studies reporting increased 
levels of 25(OH)D following statin treatment had 
small sample sizes which could lead to overestima-
tion of therapy effect, and therefore, it was difficult 
to derive any substantive conclusion. Perhaps, this 
could be the reason that most recent studies on this 
pleotropic effect of statins have failed to show any 
significant increase in vitamin D levels.19,23 A recent 
meta-analysis of data from seven studies failed to 
show any significant effect of statins treatment on 
plasma concentrations of vitamin D.9 All these re-
ports lend support to our current results indicating 
lack of association between statin use and serum 
levels of vitamin D in type 2 DM patients. The mul-
tiple linear regression model to investigate this re-
lationship while adjusting for other related factors 
mentioned above is a strength of this study.
 Our results must be seen in the context of certain 
limitations. Our collection of blood samples was 
across the whole year and the samples could not be 
divided into those collected during winter, spring or 
summer. Furthermore, no dietary information was 
obtained. However, in spite of these limitations, we 
have been able to report lack of association between 
statin use and vitamin D levels in a hospital-based 
population of type 2 DM patients using a reasonably 
large sample size. 
 In order to obtain conclusive evidence regarding 
the relationship of statin use with vitamin D status in 
South Asian population, prospective, randomized, 
placebo controlled and double blinded multicentric 
clinical trials with large sample size would be 
required.
CONCLUSION
 There is no association between statin use and 
levels of vitamin D in a hospital-based Pakistani 
population of type 2 DM patients.
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